Warner Chilcott Announces Retirement of Corporate Development Head

DUBLIN, Ireland, Aug. 26, 2011 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that Anthony Bruno, the Company's Executive Vice President, Corporate Development, will retire at the end of this year. Mr. Bruno joined the Company in March 2001 as Senior Vice President, Corporate Development and General Counsel after spending 17 years with Warner-Lambert (now Pfizer Inc.). Mr. Bruno was promoted to Executive Vice President, Corporate Development, in April 2003 and continued to serve as General Counsel until July 2005. During his tenure at the Company, Mr. Bruno directed a number of important business development transactions, including the Company's acquisition of the global branded pharmaceuticals business of The Procter & Gamble Company ("P&G") in 2009. During his remaining time with the Company, Mr. Bruno will assist with transitional matters.

Effective immediately, Michael Halstead, the Company's Senior Vice President, Corporate Development, will assume leadership of the Company's business development efforts. Mr. Halstead joined the Company's legal group in May 2005 and held positions of increasing responsibility before his promotion to his current position in June 2011. Prior to joining the Company, Mr. Halstead practiced law in the mergers and acquisitions group of Davis Polk & Wardwell LLP.

"On behalf of the Board and the Company, I would like to thank Tony for the many contributions he has made to Warner Chilcott and wish him the best in his retirement," said Roger Boissonneault, President and Chief Executive Officer. "I have worked closely with Michael on numerous strategic initiatives, including the P&G transaction, and I am confident in the continued success of our business development efforts under his leadership."

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare, gastroenterology, dermatology and urology segments of the North American and Western European pharmaceuticals markets. The Company is fully integrated with internal resources dedicated to the development, manufacturing and promotion of its products. WCRX-G


```
CONTACT: Company Contact:

         Emily Hill

         Investor Relations

         973-907-7084

         Emily.Hill@wcrx.com
```